according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version	Revision Date: 30.09.2023	SDS Number:	Date of last issue: 04.04.2023
2.1		2540879-00012	Date of first issue: 23.02.2018
-			

1. PRODUCT AND COMPANY IDENTIFICATION

Product name	:	Dexamethasone Solid Formulation
Manufacturer or supplier's de Company	eta :	ils MSD
Address	:	Briahnager - Off Pune Nagar Road Wagholi - Pune - India 412 207
Telephone	:	+1-908-740-4000
Emergency telephone number	:	+1-908-423-6000
E-mail address	:	EHSDATASTEWARD@msd.com
Recommended use of the ch	em	ical and restrictions on use
Recommended use Restrictions on use	:	Veterinary product Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Long-term (chronic) aquatic	:	Category 3
hazard		

GHS label elements

Hazard pictograms Signal word Hazard statements	:	None None H412 Harmful to aquatic life with long lasting effects.
Precautionary statements	:	Prevention: P273 Avoid release to the environment.
		Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	2540879-00012	Date of first issue: 23.02.2018

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	>= 30 - < 50
Dexamethasone	50-02-2	>= 0.25 - < 0.3

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air.
In case of skin contact	:	Get medical attention. In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed Protection of first-aiders	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.
5. FIREFIGHTING MEASURES		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam

Unsuitable extinguishing media	:	Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical None known.
Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides


according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version 2.1	Revision Date: 30.09.2023	-	0S Number: 40879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018
Spec ods	fic extinguishing meth-	:	cumstances and t Use water spray t Remove undama so.	measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do
	al protective equipment efighters	:		e, wear self-contained breathing apparatus. tective equipment.
6. ACCIDI	ENTAL RELEASE MEAS	SUF	RES	
tive e	nal precautions, protec- quipment and emer- procedures	:	Follow safe handl	tective equipment. ing advice (see section 7) and personal pro- t recommendations (see section 8).
Envir	onmental precautions	:	Retain and dispos	akage or spillage if safe to do so. se of contaminated wash water. should be advised if significant spillages
	ods and materials for inment and cleaning up	:	tainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the att Local or national posal of this mate employed in the of mine which regula Sections 13 and 1	f dust in the air (i.e., clearing dust surfaces

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use.





Dexamethasone Solid Formulation

Version 2.1	Revision Date: 30.09.2023	SDS Number: 2540879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018
	itions for safe storage rials to avoid	Take precaution Take care to previronment. Keep in properl Keep tightly clo Store in accord Do not store wi	ance with the particular national regulations. th the following product types:
		Strong oxidizing	g agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Starch	9005-25-8	TWA	10 mg/m3	ACGIH
Dexamethasone	50-02-2	TWA	10 µg/m3 (OEB 3)	Internal
	Further information	Further information: Skin		
		Wipe limit	100 µg/100 cm ²	Internal

Engineering measures :	All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face contain- ment devices). Minimize open handling.
Personal protective equipmen	t
Respiratory protection :	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.
Filter type : Hand protection	Particulates type
Material :	Chemical-resistant gloves
Remarks :	Consider double gloving.
Eye protection :	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection :	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version	Revision Date: 30.09.2023	SDS Number:	Date of last issue: 04.04.2023
2.1		2540879-00012	Date of first issue: 23.02.2018
Hygie	ne measures	flushing system place. When using do Wash contamin The effective op engineering cor appropriate deg	hemical is likely during typical use, provide eye s and safety showers close to the working not eat, drink or smoke. ated clothing before re-use. beration of a facility should include review of ntrols, proper personal protective equipment, jowning and decontamination procedures, ne monitoring, medical surveillance and the rative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-	:	Not applicable

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version 2.1	Revision Date: 30.09.2023	SDS Numb 2540879-0		Date of last issue: 04.04.2023 Date of first issue: 23.02.2018
	nol/water			
Auto	o-ignition temperature	: No dat	a available	
Dec	omposition temperature	: No dat	a available	
	osity /iscosity, kinematic	: Not ap	plicable	
Exp	losive properties	: Not ex	plosive	
Oxic	lizing properties	: The su	ibstance oi	mixture is not classified as oxidizing.
Mole	ecular weight	: No dat	a available	
Part	icle size	: No dat	a available	
Rea	BILITY AND REACTIVITY ctivity mical stability	: Not cla		a reactivity hazard. mal conditions.
	sibility of hazardous reac-	: May fo dling o	orm explosi	ve dust-air mixture during processing, han-
Con	ditions to avoid		lames and dust format	
Haz	mpatible materials ardous decomposition lucts	: Oxidizi	ing agents	composition products are known.
11. TOX		ION		
	rmation on likely routes of osure	: Inhalati Skin co Ingestio Eye co	ntact on	
Acu	te toxicity			
Not	classified based on availa	ble informat	ion.	
Con	nponents:			
Star	ch:			

Starch:		
Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg	
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg	/kg
Dexamethasone:		
Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg	
	LD50 (Mouse): > 6,500 mg	/kg

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version	Revision Date: 30.09.2023	SDS Number:	Date of last issue: 04.04.2023
2.1		2540879-00012	Date of first issue: 23.02.2018

Acute toxicity (other routes of : LD50 (Rat): 14 mg/kg administration)

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Dexamethasone:

Species	:	Rabbit
Result	:	Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species	:	Rabbit
Result	:	No eye irritation

Dexamethasone:

Species	:	Rabbit
Result	:	Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Starch:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative

Dexamethasone:

Genotoxicity in vitro

according to the Globally Harmonized System



Dexamethasone Solid Formulation

rsion	Revision Date: 30.09.2023		9S Number: 40879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018
			Result: negative	
			Test Type: in viti Test system: mo Result: negative	ro assay use lymphoma cells
Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative				
	nogenicity			
	assified based on ava	allable	information.	
•	oductive toxicity	viloble	information	
	assified based on ava	anabie		
	<u>oonents:</u>			
	methasone:		Test Type: Dave	lopment
ment	s on foetal develop-	·	Test Type: Deve Species: Mouse	lopment
				e: Subcutaneous
			•	Foxicity: LOAEL: 6 mg/kg body weight
			Result: Specific	developmental abnormalities, Cleft palate
			Species: Rabbit	
			Application Rout	
				Foxicity: NOAEL: 0.025 mg/kg body weight developmental abnormalities
			Species: Rabbit Application Rout	o: Intromuscular
			••	Foxicity: LOAEL: >= 0.062 mg/kg body weig
				developmental abnormalities
			Species: Rat	
			Application Rout	e: Subcutaneous
				Foxicity: LOAEL: >= 0.02 mg/kg body weight and visceral variations, Retardations
Repro sessn	oductive toxicity - As- nent	:	May damage the	
STOT	- single exposure			
	assified based on ava	ailable	information.	
STOT	- repeated exposure	е		
Not c	assified based on ava	ailable	information.	
Com	oonents:			
Dexa	methasone:			
	sure routes	:	Oral	
Targe	et Organs	:	Adrenal gland, li	mmune system, thymus gland

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version 2.1	Revision Date: 30.09.2023	SDS Number: 2540879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018
Asses	ssment	: May cause o exposure.	lamage to organs through prolonged or repeated
Repe	ated dose toxicity		
Comp	oonents:		
Starc	h:		
Speci	es	: Rat	
NOAE	EL	: >= 2,000 mg	/kg
	cation Route	: Skin contact	
	sure time	: 28 Days	
Metho	bd	: OECD Test	Guideline 410
Dexa	methasone:		
Speci	es	: Rat	
NOAE		: 0.0015 mg/k	q
Applic	cation Route	: Oral	5
	sure time	: 7 d	
	et Organs	: Liver	
Rema		: Significant to	oxicity observed in testing
Speci		: Rat	
LOAE		: 0.003 mg/kg)
	cation Route	: Oral	
	sure time	: 90 d	
	et Organs		nal gland, thymus gland
Rema	arks	: Significant to	oxicity observed in testing
Speci		: Rat	
LOAE		: 0.125 mg/kថ)
	cation Route	: Oral	
	sure time	: 6 Weeks	
	et Organs	: Adrenal glan	
Rema	arks	: Significant to	oxicity observed in testing
Speci		: Rat	
LOAE		: 0.4 mg/kg	
	cation Route	: Oral	
	sure time	: 3 Months	
	et Organs	: Immune sys	
Rema	arks	: Significant to	oxicity observed in testing
Speci		: Dog	
LOAE		: 8 mg/kg	
	cation Route	: Oral	
	sure time	: 3 Months	
	et Organs	: Immune sys	
Rema	arks	: Significant to	oxicity observed in testing

Aspiration toxicity

Not classified based on available information.

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version 2.1	Revision Date: 30.09.2023		OS Number: 40879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018	
Expe	rience with human ex	posi	ire		
Com	ponents:				
Dexa	methasone:				
Inges	Ingestion		Target Organs: Immune system Target Organs: Adrenal gland Target Organs: Bone Symptoms: muscle weakness		
2. ECOL	OGICAL INFORMATIC	ON			
Ecot	oxicity				
Com	ponents:				
Dexa	methasone:				
	ity to daphnia and othe tic invertebrates	r:	Exposure time:	magna (Water flea)): > 56 mg/l 48 h Test Guideline 202	
Toxicity to algae/aquatic plants		:	mg/l Exposure time:	kirchneriella subcapitata (green algae)): > 9. 72 h Test Guideline 201	
			mg/l Exposure time:	okirchneriella subcapitata (green algae)): 9.2 72 h Test Guideline 201	
Toxic	ity to microorganisms	:			
Toxicity to fish (Chronic tox- icity) : NOEC: 0.033 mg/l Exposure time: 32 d Species: Pimephales promelas Method: OECD Test Guideline		32 d hales promelas (fathead minnow)			

M-Factor (Chronic aquatic : 1 toxicity)

Persistence and degradability

Components:

Dexamethasone:

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version 2.1	Revision Date: 30.09.2023		DS Number: 40879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018	
Biode	Biodegradability		Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 3.54 d Method: OECD Test Guideline 314		
Bioaccumulative potential					
Comp	oonents:				
Partiti	Dexamethasone: Partition coefficient: n- : log Pow: 1.83 octanol/water				
No da Other	ity in soil ta available adverse effects ta available				
13. DISPO	SAL CONSIDERATIO	٧S			
Dispo	sal methods				
Waste	e from residues	:		[:] waste into sewer. ordance with local regulations.	
Conta	minated packaging	:		should be taken to an approved waste han-	

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product. **14. TRANSPORT INFORMATION**

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Versior 2.1	Revision Date: 30.09.2023		DS Number: 540879-00012	Date of last issue: 04.04.2023 Date of first issue: 23.02.2018	
Al	CS	:	not determined		
DS	SL	:	not determined		
IE	IECSC		not determined		
16. OTHER INFORMATION					
Re	Revision Date		30.09.2023		
Further information					
со	Sources of key data used to compile the Safety Data Sheet			l data, data from raw material SDSs, OECD arch results and European Chemicals Agen- Iropa.eu/	
Da	Date format		dd.mm.yyyy		
Full text of other abbreviations					
AC	GIH	:	USA. ACGIH Thr	eshold Limit Values (TLV)	
AC	ACGIH / TWA		8-hour, time-weig	hted average	

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

according to the Globally Harmonized System



Dexamethasone Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	2540879-00012	Date of first issue: 23.02.2018

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN